Other factors that may cause the Company's actual results to differ from current expectations are discussed in the Company's filings with the Securities and Exchange Commission (the "SEC"), including the section titled "Risk Factors" in the Company's Form 10-Q for the quarter ended September 30, 2025, filed with the SEC on October 28, 2025. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this presentation is given. Except as required by law, ...

Q3 2025 Financial Performance - Revenue reached $27.3 million in Q3 2025[38] - Gross profit margin was 55% in Q3 2025[38] - New patient starts totaled 5,334 in Q3 2025[13] - Approximately 70% of new patient starts in Q3 2025 came from multiple daily injections[14] - New patient starts reimbursed through pharmacy were in the low 30s % in Q3 2025[14] Strategic Initiatives - The company launched the Color iLet in October 2024, featuring a color screen and brighter display[17] - The company launched Libre 3 Plus Integration in November 2024, which is the first insulin pump in the U S to integrate with Abbott's Freestyle Libre 3 Plus[17] - The company released Bionic Portal Update in May 2025, allowing HCPs to access real-time clinical outcomes for their patients[18] - The company has effective formulary agreements in place with all major PBMs operating in the U S as of July 2025[21] - The company received iLet Special 510(k) Clearance in September 2025 for usability improvements and a faster cartridge change process[22] Full Year 2025 Guidance - The company projects total revenue to be greater than $96.5 million for the full year 2025[25] - The company anticipates a gross margin of 54-55% for the full year 2025[25] - The company expects new patient starts through pharmacy to be 27-29% for the full year 2025[25]

Q2 2025 Financial Performance - Revenue reached $23.2 million[11], a significant increase from $0.6 million in Q2 2023[11] - Gross margin was 54% in Q2 2025[11], compared to 4% in Q2 2023[11] - New patient starts totaled 4,934 in Q2 2025[11], up from 31 in Q2 2023[11] - Approximately 71% of new patient starts in Q2 2025 were reimbursed through pharmacy[13] - Net loss was $16.9 million in Q2 2025[31] Full Year 2025 Guidance - Total revenue is projected to be between $88 million and $93 million[21] - Gross margin is expected to be between 52% and 55%[21] - New patient starts through pharmacy are anticipated to be between 25% and 28%[21] Strategic Initiatives - The company launched Bionic Circle in September 2024, a remote monitoring app[16] - The company launched Color iLet in October 2024, featuring a color screen[16] - The company integrated with Abbott's Freestyle Libre 3 Plus in November 2024[16] - The company completed dosing for the Glucagon Development PK/PD bridging study in Canada in July 2025[19]